Antibody to hepatitis B surface antigen trough levels and half‐lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation
Hepatitis B immunoglobulin (HBIG) administration remains an essential component of standard reinfection prophylaxis after liver transplantation for hepatitis B virus–related liver disease. Previous studies have suggested that intramuscular (IM) HBIG administration compared to intravenous (IV) HBIG a...
Gespeichert in:
| Veröffentlicht in: | Liver transplantation 2008-04, Vol.14 (4), p.435-442 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 442 |
|---|---|
| container_issue | 4 |
| container_start_page | 435 |
| container_title | Liver transplantation |
| container_volume | 14 |
| creator | Hooman, Nazanin Rifai, Kinan Hadem, Johannes Vaske, Bernhard Philipp, Gunnar Priess, Andrea Klempnauer, Juergen Tillmann, Hans L. Manns, Michael P. Rosenau, Jens |
| description | Hepatitis B immunoglobulin (HBIG) administration remains an essential component of standard reinfection prophylaxis after liver transplantation for hepatitis B virus–related liver disease. Previous studies have suggested that intramuscular (IM) HBIG administration compared to intravenous (IV) HBIG administration may be cost‐effective and dose‐saving. To compare antibody against hepatitis B surface antigen (anti‐HBs) kinetics after IV HBIG administration versus IM HBIG administration, 24 patients received 2000 IU of HBIG every 6 weeks over a study period of 48 weeks in a crossover design. HBIG was started intravenously in 12 patients (group A) and intramuscularly in 12 patients (group B). After 4 doses, at week 24 HBIG administration was switched from IM to IV and vice versa. Anti‐HBs kinetics of 22 patients were evaluated. Mean anti‐HBs levels measured 2, 4, and 6 weeks after each HBIG administration did not differ significantly (480 ± 166, 319 ± 126, and 221 ± 106 IU/L after IV administration versus 457 ± 166, 310 ± 147, and 218 ± 112 IU/L after IM administration). Half‐lives of anti‐HBs decline (IV, 25.5 ± 6.0 days, versus IM, 24.7 ± 6.2 days) and area under the curve values from week 2 to 6 (IV, 9.4 ± 3.6 IU*day/mL, versus IM, 9.0 ± 3.9 IU*day/mL) also showed no significant difference. Variation of anti‐HBs levels after IV HBIG administration versus IM HBIG administration was neither significantly different within patients (intraindividual variance) nor between patients (interindividual variance). However, intraindividual variance was lower than interindividual variance after IV (P < 0.05) and IM (P < 0.05) HBIG administration at every time point (2, 4, and 6 weeks). In conclusion, IV HBIG administration and IM HBIG administration are equally effective with respect to the crucial pharmacokinetic parameters. That is, IM HBIG is not dose‐saving; however, it may be cost‐effective if the price per unit is lower. Individualized dosing intervals should be further evaluated as a cost‐effective alternative to fixed dosing schemes. Liver Transpl 14:435–442, 2008. © 2008 AASLD. |
| doi_str_mv | 10.1002/lt.21343 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_902339321</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>902339321</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3513-d0b79b9ea305411f8084c4a5c098417b86b846364f8d85db5fc432eaae8baa5a3</originalsourceid><addsrcrecordid>eNp9kc2OFCEUhYlx4oytiU9gWKmbGqGAKmo5Thw16cTNuK5AAd0YClp-2vTOR_CJfBifZJiujmYWuuHvfpx74ADwAqNLjFD71uXLFhNKHoELzNq-6WhPHv9Zd-wcPE3pK0IYswE9AeeYE05Qzy_AryufrQzqAHOAW70T2Wab4DuYSjRi0lDU-kZ7mGMomy10eq9dqqcKboUzv3_8dHavE1QB-pChssboCIXJdbQ-R7HXPpTlwnE_lzQVJ-KDZnaeiw8bF2Rx1kOhZuttqnS2wZ_U7vvEakP4tHPV1bH2DJwZ4ZJ-fppX4MvN-9vrj83684dP11frZiIMk0Yh2Q9y0IIgRjE2HHE6UcEmNHCKe8k7yWlHOmq44kxJZiZKWi2E5lIIJsgKvF50dzF8KzrlcbZp0q4a0fV544BaQgZSQ1iBV_8le0S7-vdDBd8s4BRDSlGbcRftLOJhxGi8T3V0eTymWtGXJ80iZ63-gqcYK9AswHfr9OGfQuP6dhG8AxEJsac</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70468309</pqid></control><display><type>article</type><title>Antibody to hepatitis B surface antigen trough levels and half‐lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Hooman, Nazanin ; Rifai, Kinan ; Hadem, Johannes ; Vaske, Bernhard ; Philipp, Gunnar ; Priess, Andrea ; Klempnauer, Juergen ; Tillmann, Hans L. ; Manns, Michael P. ; Rosenau, Jens</creator><creatorcontrib>Hooman, Nazanin ; Rifai, Kinan ; Hadem, Johannes ; Vaske, Bernhard ; Philipp, Gunnar ; Priess, Andrea ; Klempnauer, Juergen ; Tillmann, Hans L. ; Manns, Michael P. ; Rosenau, Jens</creatorcontrib><description>Hepatitis B immunoglobulin (HBIG) administration remains an essential component of standard reinfection prophylaxis after liver transplantation for hepatitis B virus–related liver disease. Previous studies have suggested that intramuscular (IM) HBIG administration compared to intravenous (IV) HBIG administration may be cost‐effective and dose‐saving. To compare antibody against hepatitis B surface antigen (anti‐HBs) kinetics after IV HBIG administration versus IM HBIG administration, 24 patients received 2000 IU of HBIG every 6 weeks over a study period of 48 weeks in a crossover design. HBIG was started intravenously in 12 patients (group A) and intramuscularly in 12 patients (group B). After 4 doses, at week 24 HBIG administration was switched from IM to IV and vice versa. Anti‐HBs kinetics of 22 patients were evaluated. Mean anti‐HBs levels measured 2, 4, and 6 weeks after each HBIG administration did not differ significantly (480 ± 166, 319 ± 126, and 221 ± 106 IU/L after IV administration versus 457 ± 166, 310 ± 147, and 218 ± 112 IU/L after IM administration). Half‐lives of anti‐HBs decline (IV, 25.5 ± 6.0 days, versus IM, 24.7 ± 6.2 days) and area under the curve values from week 2 to 6 (IV, 9.4 ± 3.6 IU*day/mL, versus IM, 9.0 ± 3.9 IU*day/mL) also showed no significant difference. Variation of anti‐HBs levels after IV HBIG administration versus IM HBIG administration was neither significantly different within patients (intraindividual variance) nor between patients (interindividual variance). However, intraindividual variance was lower than interindividual variance after IV (P < 0.05) and IM (P < 0.05) HBIG administration at every time point (2, 4, and 6 weeks). In conclusion, IV HBIG administration and IM HBIG administration are equally effective with respect to the crucial pharmacokinetic parameters. That is, IM HBIG is not dose‐saving; however, it may be cost‐effective if the price per unit is lower. Individualized dosing intervals should be further evaluated as a cost‐effective alternative to fixed dosing schemes. Liver Transpl 14:435–442, 2008. © 2008 AASLD.</description><identifier>ISSN: 1527-6465</identifier><identifier>EISSN: 1527-6473</identifier><identifier>DOI: 10.1002/lt.21343</identifier><identifier>PMID: 18383078</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adenine - analogs & derivatives ; Adenine - therapeutic use ; Adult ; Aged ; Antiviral Agents - therapeutic use ; DNA, Viral - analysis ; Drug Administration Schedule ; Female ; Hepatitis B - immunology ; Hepatitis B - prevention & control ; Hepatitis B - surgery ; Hepatitis B surface antigen ; Hepatitis B Surface Antigens - blood ; Hepatitis B virus - genetics ; Humans ; Immunoglobulins ; Immunoglobulins - therapeutic use ; Injections, Intramuscular ; Injections, Intravenous ; Intravenous administration ; Kinetics ; Liver ; Liver diseases ; Liver transplantation ; Liver Transplantation - immunology ; Male ; Middle Aged ; Organophosphonates - therapeutic use ; Pharmacokinetics ; Prophylaxis ; Recurrence</subject><ispartof>Liver transplantation, 2008-04, Vol.14 (4), p.435-442</ispartof><rights>Copyright © 2008 American Association for the Study of Liver Diseases</rights><rights>(c) 2008 AASLD.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3513-d0b79b9ea305411f8084c4a5c098417b86b846364f8d85db5fc432eaae8baa5a3</citedby><cites>FETCH-LOGICAL-c3513-d0b79b9ea305411f8084c4a5c098417b86b846364f8d85db5fc432eaae8baa5a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Flt.21343$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Flt.21343$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18383078$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hooman, Nazanin</creatorcontrib><creatorcontrib>Rifai, Kinan</creatorcontrib><creatorcontrib>Hadem, Johannes</creatorcontrib><creatorcontrib>Vaske, Bernhard</creatorcontrib><creatorcontrib>Philipp, Gunnar</creatorcontrib><creatorcontrib>Priess, Andrea</creatorcontrib><creatorcontrib>Klempnauer, Juergen</creatorcontrib><creatorcontrib>Tillmann, Hans L.</creatorcontrib><creatorcontrib>Manns, Michael P.</creatorcontrib><creatorcontrib>Rosenau, Jens</creatorcontrib><title>Antibody to hepatitis B surface antigen trough levels and half‐lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation</title><title>Liver transplantation</title><addtitle>Liver Transpl</addtitle><description>Hepatitis B immunoglobulin (HBIG) administration remains an essential component of standard reinfection prophylaxis after liver transplantation for hepatitis B virus–related liver disease. Previous studies have suggested that intramuscular (IM) HBIG administration compared to intravenous (IV) HBIG administration may be cost‐effective and dose‐saving. To compare antibody against hepatitis B surface antigen (anti‐HBs) kinetics after IV HBIG administration versus IM HBIG administration, 24 patients received 2000 IU of HBIG every 6 weeks over a study period of 48 weeks in a crossover design. HBIG was started intravenously in 12 patients (group A) and intramuscularly in 12 patients (group B). After 4 doses, at week 24 HBIG administration was switched from IM to IV and vice versa. Anti‐HBs kinetics of 22 patients were evaluated. Mean anti‐HBs levels measured 2, 4, and 6 weeks after each HBIG administration did not differ significantly (480 ± 166, 319 ± 126, and 221 ± 106 IU/L after IV administration versus 457 ± 166, 310 ± 147, and 218 ± 112 IU/L after IM administration). Half‐lives of anti‐HBs decline (IV, 25.5 ± 6.0 days, versus IM, 24.7 ± 6.2 days) and area under the curve values from week 2 to 6 (IV, 9.4 ± 3.6 IU*day/mL, versus IM, 9.0 ± 3.9 IU*day/mL) also showed no significant difference. Variation of anti‐HBs levels after IV HBIG administration versus IM HBIG administration was neither significantly different within patients (intraindividual variance) nor between patients (interindividual variance). However, intraindividual variance was lower than interindividual variance after IV (P < 0.05) and IM (P < 0.05) HBIG administration at every time point (2, 4, and 6 weeks). In conclusion, IV HBIG administration and IM HBIG administration are equally effective with respect to the crucial pharmacokinetic parameters. That is, IM HBIG is not dose‐saving; however, it may be cost‐effective if the price per unit is lower. Individualized dosing intervals should be further evaluated as a cost‐effective alternative to fixed dosing schemes. Liver Transpl 14:435–442, 2008. © 2008 AASLD.</description><subject>Adenine - analogs & derivatives</subject><subject>Adenine - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Antiviral Agents - therapeutic use</subject><subject>DNA, Viral - analysis</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Hepatitis B - immunology</subject><subject>Hepatitis B - prevention & control</subject><subject>Hepatitis B - surgery</subject><subject>Hepatitis B surface antigen</subject><subject>Hepatitis B Surface Antigens - blood</subject><subject>Hepatitis B virus - genetics</subject><subject>Humans</subject><subject>Immunoglobulins</subject><subject>Immunoglobulins - therapeutic use</subject><subject>Injections, Intramuscular</subject><subject>Injections, Intravenous</subject><subject>Intravenous administration</subject><subject>Kinetics</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>Liver transplantation</subject><subject>Liver Transplantation - immunology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Organophosphonates - therapeutic use</subject><subject>Pharmacokinetics</subject><subject>Prophylaxis</subject><subject>Recurrence</subject><issn>1527-6465</issn><issn>1527-6473</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc2OFCEUhYlx4oytiU9gWKmbGqGAKmo5Thw16cTNuK5AAd0YClp-2vTOR_CJfBifZJiujmYWuuHvfpx74ADwAqNLjFD71uXLFhNKHoELzNq-6WhPHv9Zd-wcPE3pK0IYswE9AeeYE05Qzy_AryufrQzqAHOAW70T2Wab4DuYSjRi0lDU-kZ7mGMomy10eq9dqqcKboUzv3_8dHavE1QB-pChssboCIXJdbQ-R7HXPpTlwnE_lzQVJ-KDZnaeiw8bF2Rx1kOhZuttqnS2wZ_U7vvEakP4tHPV1bH2DJwZ4ZJ-fppX4MvN-9vrj83684dP11frZiIMk0Yh2Q9y0IIgRjE2HHE6UcEmNHCKe8k7yWlHOmq44kxJZiZKWi2E5lIIJsgKvF50dzF8KzrlcbZp0q4a0fV544BaQgZSQ1iBV_8le0S7-vdDBd8s4BRDSlGbcRftLOJhxGi8T3V0eTymWtGXJ80iZ63-gqcYK9AswHfr9OGfQuP6dhG8AxEJsac</recordid><startdate>200804</startdate><enddate>200804</enddate><creator>Hooman, Nazanin</creator><creator>Rifai, Kinan</creator><creator>Hadem, Johannes</creator><creator>Vaske, Bernhard</creator><creator>Philipp, Gunnar</creator><creator>Priess, Andrea</creator><creator>Klempnauer, Juergen</creator><creator>Tillmann, Hans L.</creator><creator>Manns, Michael P.</creator><creator>Rosenau, Jens</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>200804</creationdate><title>Antibody to hepatitis B surface antigen trough levels and half‐lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation</title><author>Hooman, Nazanin ; Rifai, Kinan ; Hadem, Johannes ; Vaske, Bernhard ; Philipp, Gunnar ; Priess, Andrea ; Klempnauer, Juergen ; Tillmann, Hans L. ; Manns, Michael P. ; Rosenau, Jens</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3513-d0b79b9ea305411f8084c4a5c098417b86b846364f8d85db5fc432eaae8baa5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adenine - analogs & derivatives</topic><topic>Adenine - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Antiviral Agents - therapeutic use</topic><topic>DNA, Viral - analysis</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Hepatitis B - immunology</topic><topic>Hepatitis B - prevention & control</topic><topic>Hepatitis B - surgery</topic><topic>Hepatitis B surface antigen</topic><topic>Hepatitis B Surface Antigens - blood</topic><topic>Hepatitis B virus - genetics</topic><topic>Humans</topic><topic>Immunoglobulins</topic><topic>Immunoglobulins - therapeutic use</topic><topic>Injections, Intramuscular</topic><topic>Injections, Intravenous</topic><topic>Intravenous administration</topic><topic>Kinetics</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>Liver transplantation</topic><topic>Liver Transplantation - immunology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Organophosphonates - therapeutic use</topic><topic>Pharmacokinetics</topic><topic>Prophylaxis</topic><topic>Recurrence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hooman, Nazanin</creatorcontrib><creatorcontrib>Rifai, Kinan</creatorcontrib><creatorcontrib>Hadem, Johannes</creatorcontrib><creatorcontrib>Vaske, Bernhard</creatorcontrib><creatorcontrib>Philipp, Gunnar</creatorcontrib><creatorcontrib>Priess, Andrea</creatorcontrib><creatorcontrib>Klempnauer, Juergen</creatorcontrib><creatorcontrib>Tillmann, Hans L.</creatorcontrib><creatorcontrib>Manns, Michael P.</creatorcontrib><creatorcontrib>Rosenau, Jens</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Liver transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hooman, Nazanin</au><au>Rifai, Kinan</au><au>Hadem, Johannes</au><au>Vaske, Bernhard</au><au>Philipp, Gunnar</au><au>Priess, Andrea</au><au>Klempnauer, Juergen</au><au>Tillmann, Hans L.</au><au>Manns, Michael P.</au><au>Rosenau, Jens</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibody to hepatitis B surface antigen trough levels and half‐lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation</atitle><jtitle>Liver transplantation</jtitle><addtitle>Liver Transpl</addtitle><date>2008-04</date><risdate>2008</risdate><volume>14</volume><issue>4</issue><spage>435</spage><epage>442</epage><pages>435-442</pages><issn>1527-6465</issn><eissn>1527-6473</eissn><abstract>Hepatitis B immunoglobulin (HBIG) administration remains an essential component of standard reinfection prophylaxis after liver transplantation for hepatitis B virus–related liver disease. Previous studies have suggested that intramuscular (IM) HBIG administration compared to intravenous (IV) HBIG administration may be cost‐effective and dose‐saving. To compare antibody against hepatitis B surface antigen (anti‐HBs) kinetics after IV HBIG administration versus IM HBIG administration, 24 patients received 2000 IU of HBIG every 6 weeks over a study period of 48 weeks in a crossover design. HBIG was started intravenously in 12 patients (group A) and intramuscularly in 12 patients (group B). After 4 doses, at week 24 HBIG administration was switched from IM to IV and vice versa. Anti‐HBs kinetics of 22 patients were evaluated. Mean anti‐HBs levels measured 2, 4, and 6 weeks after each HBIG administration did not differ significantly (480 ± 166, 319 ± 126, and 221 ± 106 IU/L after IV administration versus 457 ± 166, 310 ± 147, and 218 ± 112 IU/L after IM administration). Half‐lives of anti‐HBs decline (IV, 25.5 ± 6.0 days, versus IM, 24.7 ± 6.2 days) and area under the curve values from week 2 to 6 (IV, 9.4 ± 3.6 IU*day/mL, versus IM, 9.0 ± 3.9 IU*day/mL) also showed no significant difference. Variation of anti‐HBs levels after IV HBIG administration versus IM HBIG administration was neither significantly different within patients (intraindividual variance) nor between patients (interindividual variance). However, intraindividual variance was lower than interindividual variance after IV (P < 0.05) and IM (P < 0.05) HBIG administration at every time point (2, 4, and 6 weeks). In conclusion, IV HBIG administration and IM HBIG administration are equally effective with respect to the crucial pharmacokinetic parameters. That is, IM HBIG is not dose‐saving; however, it may be cost‐effective if the price per unit is lower. Individualized dosing intervals should be further evaluated as a cost‐effective alternative to fixed dosing schemes. Liver Transpl 14:435–442, 2008. © 2008 AASLD.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>18383078</pmid><doi>10.1002/lt.21343</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1527-6465 |
| ispartof | Liver transplantation, 2008-04, Vol.14 (4), p.435-442 |
| issn | 1527-6465 1527-6473 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_902339321 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
| subjects | Adenine - analogs & derivatives Adenine - therapeutic use Adult Aged Antiviral Agents - therapeutic use DNA, Viral - analysis Drug Administration Schedule Female Hepatitis B - immunology Hepatitis B - prevention & control Hepatitis B - surgery Hepatitis B surface antigen Hepatitis B Surface Antigens - blood Hepatitis B virus - genetics Humans Immunoglobulins Immunoglobulins - therapeutic use Injections, Intramuscular Injections, Intravenous Intravenous administration Kinetics Liver Liver diseases Liver transplantation Liver Transplantation - immunology Male Middle Aged Organophosphonates - therapeutic use Pharmacokinetics Prophylaxis Recurrence |
| title | Antibody to hepatitis B surface antigen trough levels and half‐lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T01%3A18%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibody%20to%20hepatitis%20B%20surface%20antigen%20trough%20levels%20and%20half%E2%80%90lives%20do%20not%20differ%20after%20intravenous%20and%20intramuscular%20hepatitis%20B%20immunoglobulin%20administration%20after%20liver%20transplantation&rft.jtitle=Liver%20transplantation&rft.au=Hooman,%20Nazanin&rft.date=2008-04&rft.volume=14&rft.issue=4&rft.spage=435&rft.epage=442&rft.pages=435-442&rft.issn=1527-6465&rft.eissn=1527-6473&rft_id=info:doi/10.1002/lt.21343&rft_dat=%3Cproquest_cross%3E902339321%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70468309&rft_id=info:pmid/18383078&rfr_iscdi=true |